RT Journal Article
SR Electronic
T1 Unveiling the Dual Benefits of Bosentan in Systemic Sclerosis: Risk and Relief
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.2025-0049
DO 10.3899/jrheum.2025-0049
A1 Lammi, Matthew R.
A1 Mukherjee, Monica
YR 2025
UL http://www.jrheum.org/content/early/2025/02/11/jrheum.2025-0049.abstract
AB Digital ulcers (DUs) are a frequent and debilitating complication of systemic sclerosis (SSc), affecting approximately 50% to 70% of patients during their disease course.1 These ischemic lesions result from severe microvascular dysfunction and impaired tissue perfusion inherent to the autoimmune vasculopathy underlying SSc pathogenesis.2,3